{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:32:28Z","timestamp":1789561948020,"version":"build-2803163510"},"reference-count":33,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti\u2010angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first\u2010line treatment of advanced ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      In this single\u2010arm prospective phase II trial, patients with unresectable locally advanced or recurrent\/metastatic ESCC received camrelizumab 200\u00a0mg, liposomal paclitaxel 150\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and nedaplatin 50\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 1, and apatinib 250\u00a0mg on days 1\u201014. The treatments were repeated every 14 days for up to 9 cycles, followed by maintenance therapy with camrelizumab and apatinib. The primary endpoint was objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Secondary endpoints included disease control rate (DCR), progression\u2010free survival (PFS), overall survival (OS), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">We enrolled 30 patients between August 7, 2018 and February 23, 2019. The median follow\u2010up was 24.98 months (95% confidence interval [CI]: 23.05\u201026.16 months). The centrally assessed ORR was 80.0% (95% CI: 61.4%\u201092.3%), with a median duration of response of 9.77 months (range: 1.54 to 24.82+ months). The DCR reached 96.7% (95% CI: 82.8%\u201099.9%). The median PFS was 6.85 months (95% CI: 4.46\u201014.20 months), and the median OS was 19.43 months (95% CI: 9.93 months \u2013 not reached). The most common grade 3\u20104 treatment\u2010related adverse events (AEs) were leukopenia (83.3%), neutropenia (60.0%), and increased aspartate aminotransferase level (26.7%). Treatment\u2010related serious AEs included febrile neutropenia, leukopenia, and anorexia in one patient (3.3%), and single cases of increased blood bilirubin level (3.3%) and toxic epidermal necrolysis (3.3%). No treatment\u2010related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Camrelizumab plus apatinib combined with liposomal paclitaxel and nedaplatin as first\u2010line treatment demonstrated feasible anti\u2010tumor activity and manageable safety in patients with advanced ESCC. Randomized trials to evaluate this new combination strategy are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">This trial was registered on July 27, 2018, at ClinicalTrials.gov (identifier: NCT03603756).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.12119","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T12:50:43Z","timestamp":1607777443000},"page":"711-720","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first\u2010line treatment of advanced esophageal squamous cell carcinoma"],"prefix":"10.34133","volume":"40","author":[{"given":"Bo","family":"Zhang","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qi","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Bai","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Medicine Co. Ltd.","place":["Lianyungang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-8385","authenticated-orcid":false,"given":"Jing","family":"Huang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308124"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/cco.2017.07.06","article-title":"Systemic therapy for esophageal cancer: chemotherapy","volume":"6","author":"Ku GY","year":"2017","unstructured":"Ku GY. Systemic therapy for esophageal cancer: chemotherapy. Chin Clin Oncol 2017;6:49.","journal-title":"Chin Clin Oncol"},{"key":"e_1_3_2_5_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology . Esophageal and Esophagogastric Junction Cancers Version 4. 2020 \u2013 August 14 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed Oct 3 2020."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdy498","article-title":"Pan\u2010Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO\u2010ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro K","year":"2019","unstructured":"Muro K, Lordick F, Tsushima T, et\u00a0al. Pan\u2010Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO\u2010ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology : Official Journal of the European Society for Medical Oncology 2019;30:34\u201043.","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"key":"e_1_3_2_7_2","first-page":"172","article-title":"Phase II evaluation of cisplatin and 5\u2010fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial","volume":"22","author":"Iizuka T","year":"1992","unstructured":"Iizuka T, Kakegawa T, Ide H, et\u00a0al. Phase II evaluation of cisplatin and 5\u2010fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22:172\u20106.","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","article-title":"Randomised phase II study of cisplatin and 5\u2010fluorouracil (5\u2010FU) versus cisplatin alone in advanced squamous cell oesophageal cancer","volume":"33","author":"Bleiberg H","year":"1997","unstructured":"Bleiberg H, Conroy T, Paillot B, et\u00a0al. Randomised phase II study of cisplatin and 5\u2010fluorouracil (5\u2010FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216\u201020.","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12032-012-0343-4","article-title":"A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy","volume":"30","author":"Huang J","year":"2013","unstructured":"Huang J, Zhou Y, Zhang H, et\u00a0al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol 2013;30:343.","journal-title":"Med Oncol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00280-008-0874-8","article-title":"Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma","volume":"64","author":"Gong Y","year":"2009","unstructured":"Gong Y, Ren L, Zhou L, et\u00a0al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol 2009;64:327\u201033.","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jjco\/hyp058","article-title":"A phase II study of paclitaxel and nedaplatin as first\u2010line chemotherapy in patients with advanced esophageal cancer","volume":"39","author":"Cao W","year":"2009","unstructured":"Cao W, Xu C, Lou G, et\u00a0al. A phase II study of paclitaxel and nedaplatin as first\u2010line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol 2009;39:582\u201087.","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4143\/crt.2016.121","article-title":"Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer","volume":"49","author":"Kim M","year":"2017","unstructured":"Kim M, Keam B, Kim TM, et\u00a0al. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Res Treat 2017;49:416\u201022.","journal-title":"Cancer Res Treat"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1442-2050.2010.01070.x","article-title":"Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma","volume":"23","author":"Honda M","year":"2010","unstructured":"Honda M, Miura A, Izumi Y, et\u00a0al. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus 2010;23:641\u20105.","journal-title":"Dis Esophagus"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/JTO.0b013e3181c1ffd5","article-title":"Phase I\/II study of docetaxel\/cisplatin\/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma","volume":"5","author":"Takahashi H","year":"2010","unstructured":"Takahashi H, Arimura Y, Yamashita K, et\u00a0al. Phase I\/II study of docetaxel\/cisplatin\/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 2010;5:122\u20108.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2018-0653","article-title":"Phase II Trial of 5\u2010Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer","volume":"24","author":"Ueda H","year":"2019","unstructured":"Ueda H, Kawakami H, Nonagase Y, et\u00a0al. Phase II Trial of 5\u2010Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist 2019;24:163\u2010e176.","journal-title":"Oncologist"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1471-2407-11-385","article-title":"Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma","volume":"11","author":"Yun T","year":"2011","unstructured":"Yun T, Han JY, Lee JS, et\u00a0al. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer 2011;11:385.","journal-title":"BMC Cancer"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30181-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE\u2010180 Study","volume":"5","author":"Shah MA","year":"2019","unstructured":"Shah MA, Kojima T, Hochhauser D, et\u00a0al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE\u2010180 Study. JAMA Oncol 2019;5:546\u201050.","journal-title":"JAMA Oncol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, Activity, and Biomarkers of SHR\u20101210, an Anti\u2010PD\u20101 Antibody, for Patients with Advanced Esophageal Carcinoma","volume":"24","author":"Huang J","year":"2018","unstructured":"Huang J, Xu B, Mo H, et\u00a0al. Safety, Activity, and Biomarkers of SHR\u20101210, an Anti\u2010PD\u20101 Antibody, for Patients with Advanced Esophageal Carcinoma. Clinical cancer Research : an Official Journal of the American Association for Cancer Research 2018;24:1296\u20101304.","journal-title":"Clinical cancer Research : an Official Journal of the American Association for Cancer Research"},{"key":"e_1_3_2_20_2","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION\u20103): a multicentre, randomised, open\u2010label, phase 3 trial","author":"Kato K","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et\u00a0al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION\u20103): a multicentre, randomised, open\u2010label, phase 3 trial. Lancet Oncol 2019.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second\u2010line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open\u2010label, phase 3 study","volume":"21","author":"Huang J","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et\u00a0al. Camrelizumab versus investigator's choice of chemotherapy as second\u2010line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open\u2010label, phase 3 study. Lancet Oncol 2020;21:832\u201042.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/bjc.2015.197","article-title":"A phase II and pharmacodynamic study of sunitinib in relapsed\/refractory oesophageal and gastro\u2010oesophageal cancers","volume":"113","author":"Wu C","year":"2015","unstructured":"Wu C, Mikhail S, Wei L, et\u00a0al. A phase II and pharmacodynamic study of sunitinib in relapsed\/refractory oesophageal and gastro\u2010oesophageal cancers. Br J Cancer 2015;113:220\u20105.","journal-title":"Br J Cancer"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.2147\/OTT.S132756","article-title":"Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma","volume":"10","author":"Li J","year":"2017","unstructured":"Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther 2017;10:3965\u201069.","journal-title":"Onco Targets Ther"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.2019.37.4_suppl.95","article-title":"Anlotinib in chemotherapy\u2010refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double\u2010blind, multicenter phase II trial","volume":"37","author":"Huang J","year":"2019","unstructured":"Huang J, Xiao J, Fang W, et\u00a0al. Anlotinib in chemotherapy\u2010refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double\u2010blind, multicenter phase II trial. J Clin Oncol 2019;37:95\u20105.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5\u2010Fluorouracil selectively kills tumor\u2010associated myeloid\u2010derived suppressor cells resulting in enhanced T cell\u2010dependent antitumor immunity","volume":"70","author":"Vincent J","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, et\u00a0al. 5\u2010Fluorouracil selectively kills tumor\u2010associated myeloid\u2010derived suppressor cells resulting in enhanced T cell\u2010dependent antitumor immunity. Cancer Res 2010;70:3052\u201061.","journal-title":"Cancer Res"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum\u2010based drugs disrupt STAT6\u2010mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis WJ","year":"2011","unstructured":"Lesterhuis WJ, Punt CJ, Hato SV, et\u00a0al. Platinum\u2010based drugs disrupt STAT6\u2010mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100\u20108.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross\u2010presentation, cross\u2010priming rather than cross\u2010tolerizing host tumor\u2010specific CD8 T cells","volume":"170","author":"Nowak AK","year":"2003","unstructured":"Nowak AK, Lake RA, Marzo AL, et\u00a0al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross\u2010presentation, cross\u2010priming rather than cross\u2010tolerizing host tumor\u2010specific CD8 T cells. J Immunol 2003;170:4905\u201013.","journal-title":"J Immunol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw217"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9552-y"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First\u2010Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et\u00a0al. Atezolizumab for First\u2010Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018;378:2288\u2010301.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2019.37.4_suppl.2","article-title":"Pembrolizumab versus chemotherapy as second\u2010line therapy for advanced esophageal cancer: Phase III KEYNOTE\u2010181 study","volume":"37","author":"Kojima T","year":"2019","unstructured":"Kojima T, Muro K, Francois E, et\u00a0al. Pembrolizumab versus chemotherapy as second\u2010line therapy for advanced esophageal cancer: Phase III KEYNOTE\u2010181 study. J Clin Oncol 2019;37:2\u20102.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti\u2010tumour activity, and pharmacokinetics of fixed\u2010dose SHR\u20101210, an anti\u2010PD\u20101 antibody in advanced solid tumours: a dose\u2010escalation, phase 1 study","volume":"119","author":"Mo H","year":"2018","unstructured":"Mo H, Huang J, Xu J, et\u00a0al. Safety, anti\u2010tumour activity, and pharmacokinetics of fixed\u2010dose SHR\u20101210, an anti\u2010PD\u20101 antibody in advanced solid tumours: a dose\u2010escalation, phase 1 study. Br J Cancer 2018;119:538\u201045.","journal-title":"Br J Cancer"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cac2.12119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cac2.12119","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:55:53Z","timestamp":1773824153000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/cac2.12119"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12119","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2020-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}